Dabigatran: an important choice for anticoagulant therapy

Dabigatran is a direct oral anticoagulant (DOAC) mainly used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). Its mechanism of action is to exert an anticoagulant effect by directly inhibiting thrombin (factor IIa). Compared with warfarin, dabigatran does not require routine monitoring of coagulation function and has fewer drug interactions. This article will introduce the mechanism of action, clinical application, precautions and manufacturers to help readers fully understand this drug.

Dabigatran’s mechanism of action and advantages

Dabigatran blocks the coagulation cascade by directly inhibiting thrombin (factor IIa), thereby effectively preventing thrombosis. Its advantages include:fixed dose administration(No need for frequent adjustments),Quick onset of action(peak concentration within 2 hours), andLower risk of intracranial hemorrhage. Clinical studies have shown that dabigatran is more effective than warfarin in preventing stroke in patients with atrial fibrillation (RE-LY trial). In addition, its metabolism is mainly excreted by the kidneys, so patients with renal insufficiency require dose adjustment.

Clinical applications and indications

Approved indications for dabigatran include:Stroke prevention in patients with nonvalvular atrial fibrillation(150mg twice daily),DVT/PE treatment and recurrence prevention(150mg or 110mg twice daily). For patients who are elderly (≥80 years old) or at high risk of bleeding, the 110 mg dose can be used. It should be noted that dabigatran is not suitable for patients with mechanical valves or severe valvular disease. Renal function should be assessed regularly during medication (disabled when CrCl <30mL/min) and signs of bleeding.

Precautions and adverse reactions

Common adverse reactions of dabigatran includegastrointestinal symptoms(such as indigestion, heartburn) andBleeding risk(The incidence rate is about 16%). It is necessary to avoid combined use with strong P-gp inhibitors (such as dronedarone) during medication. If bleeding occurs, useIdarucizumab(Specific reversal agent) Emergency treatment. Patients should inform their doctor about all medications they are taking and avoid strenuous exercise or trauma to reduce the risk of bleeding.

Summary and production information

Dabigatran, as a new anticoagulant, provides a more convenient treatment option for patients with atrial fibrillation and venous thrombosis. Its efficacy and safety have been verified by multiple large-scale clinical trials, but the principle of individualized medication must be strictly followed. Currently, major global manufacturers include:

Data source:1. RE-LY clinical trial (New England Journal of Medicine, 2009);2. Chinese expert consensus on clinical application of dabigatran etexilate (2021);3. Boehringer Ingelheim drug instructions.